GlassScriptPhysician profile
Brian Christopher Payne
NPI 1124343231
$4,580.57
in general payments reported to CMS, 2019-2025
28 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $110 · 2021: $178 · 2022: $648 · 2023: $722 · 2024: $592 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193 · Travel and Lodging: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.56 |
| Travel and Lodging | $868.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,274.88 | 2025 | Triclip |
| Boston Scientific Corporation | $603.36 | 2019-2023 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $291.01 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $240.31 | 2019-2024 | Xarelto |
| Pfizer INC. | $240.28 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $217.44 | 2019-2023 | Camzyos |
| Amgen INC. | $209.91 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $189.12 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.09 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $133.00 | 2019-2025 | |
| Integra Lifesciences Corporation | $128.68 | 2025 | Cusa Clarity, Codman Hakim, Duraseal Exact Spinal Sealant System |
| Actelion Pharmaceuticals US, INC. | $122.18 | 2019-2022 | |
| Edwards Lifesciences Corporation | $98.04 | 2024 | Pascal |
| Cvrx, INC. | $94.57 | 2024 | Barostim Neo System |
| Baxter Healthcare | $92.93 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $72.30 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.27 | 2022 | |
| Irhythm Technologies, INC. | $64.79 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $54.69 | 2019 | |
| Medtronic Vascular, INC. | $42.75 | 2019 | |
| Merck Sharp & Dohme LLC | $40.42 | 2024-2025 | Verquvo |
| Lantheus Medical Imaging, INC. | $34.09 | 2019-2021 | |
| Esperion Therapeutics, INC. | $29.09 | 2021 | |
| Philips North America LLC | $26.53 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Kestra Medical Technology Services, INC. | $19.70 | 2024 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $17.13 | 2025 | |
| Arbor Pharmaceuticals, INC. | $15.01 | 2019 | |
| Celonova Biosciences, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.